NewcelX Ltd.

Contributing Author

Recent Articles by NewcelX Ltd.

Jul-31	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing NCEL GlobeNewswire
Jul-15	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio NCEL GlobeNewswire
Jul-08	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board NCEL +5.49% GlobeNewswire
Jul-01	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes NCEL +5.19% GlobeNewswire
May-27	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes NCEL +9.52% GlobeNewswire
Apr-30	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 NCEL +28.95% GlobeNewswire
Apr-20	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference NCEL +6.39% GlobeNewswire
Apr-01	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing NCEL +10.85% GlobeNewswire